Covid 19 Research using Clinical Trials (Home Page)
Flow controlled ventilation (Evone-ventilator)Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
|
Name (Synonyms) |
Correlation |
Correlated MeSH Terms (4)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
The pandemic of a newly upcoming viral disease which is associated with COVID-19 puts the
whole world's health system under pressure.
Patients suffering from this disease mainly develop respiratory symptoms, which can lead to
severe acute respiratory distress syndrome (ARDS) necessitating ICU, admission in 10-20% of
the cases admitted to hospital. In addition to these symptoms, patients show lymphopenia,
cardiac symptoms and altered coagulation profiles. Although those patients are treated in the
ICU the mortality is up to 20% due to multiorgan failure. The aim of this study is to show
non-inferiority of flow-controlled ventilation compared to standard (lung protective
ventilation).
Methods:
After admission to the ICU, the patients will receive information about the study and
informed consent will be taken. Upon reaching the criteria for moderate to severe ARDS (P/F
ratio below 200 mmHg and PEEP above 5 cmH2O) the patients will be randomized. In the
treatment group (group A) the ultra-thin ventilation tube will be placed through the existing
tube. Then flow-controlled ventilation will be applied for 48 hours. In the other group
(group B) ventilation will be performed according to the lung protective strategy. All other
treatment will be unchanged.
Data-collection will be started 1 hour after initiation of the study. Primary end point is
PaO2.
NCT04399317 ARDS Associated With COVID-19 Device: Flow controlled ventilation (Evone-ventilator)
Primary Outcomes
Measure: arterial oxygen partial pressure (PaO2) Time: during 48 hours of treatment
No related HPO nodes (Using clinical trials)